• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21959 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Smoking bans in public places]
2009     Committee for New Health Technology Assessment (CNHTA) [SMN1/SMN2 gene [Gene dosage test]]
2009     Committee for New Health Technology Assessment (CNHTA) [SMN1 gene, mutation[sequencing]]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Small study effect and publication bias in systematic reviews with meta-analyses]
2009     Committee for New Health Technology Assessment (CNHTA) [Small bowel transplantation]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Sling suspension in male urinary incontinence]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sleep position therapy for obstructive sleep apnoea]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sleep position therapy for obstructive sleep apnoea - Addendum to commission E20-07]
2008     Committee for New Health Technology Assessment (CNHTA) [SLC25A13 gene, mutation[sequencing]]
2009     Committee for New Health Technology Assessment (CNHTA) [SLC12A3 gene, mutation [sequencing]]
2022     National Authority for Assessment and Accreditation in Healthcare (INEAS) [SKYRIZI® (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults : A rapid review]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Skin substitutes in burn care]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin/metformin - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin/Metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sirolimus (Facial angiofibroma in tuberous sclerosis) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipuleucel-T (Addendum to Commission A14-38)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipuleucel-T - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Siponimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Siponimod (multiple sclerosis) - Addendum to Commission A20-10]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Single-use negative pressure wound therapy for acute and chronic wounds]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Single-donor platelet concentrate in patients with thrombocytopenia]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Simoctocog alfa - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Andalusian Health Technology Assessment Area (AETSA) [Simeprevir in the treatment of chronic hepatitis C. Comparative efficacy and safety assessment]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Simeprevir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2010     The Swedish Council on Health Technology Assessment (SBU) [Silver-releasing dressings in treating chronic wounds]
2010     Committee for New Health Technology Assessment (CNHTA) [Silver in situ hybridization]
2010     Committee for New Health Technology Assessment (CNHTA) [Silver in situ hybridization test]
2010     The Swedish Council on Health Technology Assessment (SBU) [Silver dressings to treat chronic wounds]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Siltuximab - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2020     National Committee for Technology Incorporation (CONITEC) [Sibutramine for the treatment of obese patients]
2011     Committee for New Health Technology Assessment (CNHTA) [Sialendoscopy]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Sialendoscopy for the management of obstructive salivary gland disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Sialendoscopy for obstructive salivary gland disease]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Shoulder prosthesis in complex proximal humeral fractures]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Shoulder pain: appropriateness use of diagnostic imaging tests]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Shoulder arthroscopy: appropriate use]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Should one or two embryos be transferred in IVF]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Shear-wave elastography for liver fibrosis]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Shared care in catheterization of patients with long-term urinary catheter need]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [SGLT2 inhibitors in heart failure]
2009     Committee for New Health Technology Assessment (CNHTA) [SGCE gene, mutation[sequencing]]
2007     Basque Office for Health Technology Assessment (OSTEBA) [Sexually transmitted diseases. Situation in the Basque Autonomous Community. Effectiveness of preventive measures]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Setting research priorities, optimizing study design, and guiding the choice of relevant outcome measures in the evaluation of diagnostic (imaging) tests: an ancillary study of project numbers 1015 and 1139]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (obesity and control of hunger in POMC, PCSK1 or LEPR deficiency obesity) - Assessment according to §35a (para. 1, sentence 11) Social Code Book VAuftraggeber: G-BA]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (Bardet Biedl syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Serum procalcitonin levels as a diagnosis tool in acute bacterial respiratory tract infections]
2010     Andalusian Health Technology Assessment Area (AETSA) [Serum biomarkers panel for detecting early stage ovarian cancer]
2009     Committee for New Health Technology Assessment (CNHTA) [SERPINC1 exon deletion/duplication test [MLPA]]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Seroprevalence of Trypanosoma Cruzi infection in Latin American women of fertile age and during pregnancy in the Autonomous Community of the Basque Country]
1997     Finnish Office for Health Care Technology Assessment (Finohta) [Separate health care registers: a study of national and regional patient registers in Finland]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Seoul Cognitive Status Test]
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Sentinel lymph node biopsy in oral cavity carcinoma: clinical effectiveness, safety, and cost-effectiveness]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Sentinel lymph node biopsy in breast cancer treatment: indications and contraindications]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Sentinel lymph node biopsy in breast cancer management: technical aspects]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Sensor-augmented insulin pump for diabetic patients]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Addendum to Commission A20-93]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (treatment of neurofibromas in neurofibromatosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (advanced NSCLC with RET fusion) - Benefit assessment according to § 35a SGB V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, fifth line) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Selfmonitored anticoagulant therapy]
2011     Haute Autorite de sante (HAS) [Self-monitoring of blood glucose in type 2 diabetes: limited use for a target population]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Self-monitoring of blood glucose in adult patients with Type 2 Diabetes not using insulin]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Self-management of asthma supported by hospitals, ICT, nurses and general practitioners]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Self-application of an active motion splint within the treatment of ankle fractures]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Selexipag in pulmonary hypertension]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selexipag - Benefit assessment according to §35a Social Code Book V]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression]
2007     Andalusian Health Technology Assessment Area (AETSA) [Selective screening for lung cancer with chest CT]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Selection of preterm neonates at risk for neurodevelopmental disorders by segmentation of the brain using MRI]
2011     Haute Autorite de sante (HAS) [Selection of iron metabolism tests in cases where iron deficiency is suspected]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selection of interventions for the "second opinion" procedure according to § 27b Social Code Book V - Rapid Report]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Selection of health priorities: criteria, process and strategic framework. Systematic review]
2015     Andalusian Health Technology Assessment Area (AETSA) [Selection criteria for direct antiviral agents for patients with chronic hepatitis c in the SSPA]
2014     Andalusian Health Technology Assessment Area (AETSA) [Selection criteria for direct antiviral agents for patients with chronic hepatitis c in a severe clinical situation in the SSPA]
2018     Canary Health Service [SEEKER System for the screening of lysosomal storage diseases]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (psoriatic arthritis) - Addendum to Commission A20-80]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (plaque psoriasis) - Addendum to Commission A17-08]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (plaque psoriasis in children and adolescents) - Addendum to Commission A20-78]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (juvenile psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V]